Novo Nordisk + OpenAI

Novo Nordisk said Tuesday it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial work on obesity medicines. (finance.yahoo.com) The Danish drugmaker said OpenAI’s tools will help analyze large datasets, spot promising drug candidates and shorten the time from research to patient use. Novo said the rollout starts with pilot programs across research and development, manufacturing and commercial teams, with full integration expected by the end of 2026. (cnbc.com) (pharmaceutical-technology.com) Drug discovery is partly a search problem: researchers sift through huge volumes of biology, chemistry and trial data to find molecules worth testing. Novo said OpenAI’s systems will also be used in supply chains, distribution and corporate operations, not just in labs. (money.usnews.com) (biospace.com) Novo is making the move as competition in obesity drugs has tightened. Reuters reported the company has fallen behind Eli Lilly in the weight-loss market, and CNBC reported in February that Lilly had taken a clear edge in market share as Novo prepared for a sales decline this year. (finance.yahoo.com) (cnbc.com) The partnership also extends an artificial intelligence push Novo had already started. Nvidia said in June 2025 that it was working with Novo Nordisk and the Danish Centre for AI Innovation to build custom models and agents for early research and clinical development using Denmark’s Gefion supercomputer. (investor.nvidia.com) Novo said the OpenAI deal includes “strict data governance” and human oversight, a point drugmakers now emphasize as they bring generative artificial intelligence into regulated work. The company also said the partnership is meant to upskill its workforce and help teams work faster, not hand decisions to software alone. (biospace.com) (moneycontrol.com) Novo’s best-known obesity and diabetes brands, Wegovy and Ozempic, turned the company into one of Europe’s most valuable drugmakers. Tuesday’s announcement shows Novo is now betting that faster data analysis and faster internal execution can help it find the next medicines before rivals widen their lead. (techxplore.com) (cnbc.com)